AR110590A1 - Activador de nrf2 - Google Patents

Activador de nrf2

Info

Publication number
AR110590A1
AR110590A1 ARP170103684A ARP170103684A AR110590A1 AR 110590 A1 AR110590 A1 AR 110590A1 AR P170103684 A ARP170103684 A AR P170103684A AR P170103684 A ARP170103684 A AR P170103684A AR 110590 A1 AR110590 A1 AR 110590A1
Authority
AR
Argentina
Prior art keywords
alkyl
membered
alkynyl
alkenyl
carbocyclyl
Prior art date
Application number
ARP170103684A
Other languages
English (en)
Inventor
Vloten Kurt D Van
John H Jones
Teyu Chen
Istvan Enyedy
Zhili Xin
Andrew George Capacci
Edward Yin Lin
- Lucas Brian Stuart Shiang
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of AR110590A1 publication Critical patent/AR110590A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Se proporcionan compuestos, sales farmacéuticamente aceptables de estos, métodos para su uso y producción. Reivindicación 1: Un compuesto representado por la fórmula (1), o una sal farmacéuticamente aceptable de este, donde R¹ es -CN, -C(O)Rᵃ, CH₃S(O)₂- o alquilo C₁₋₈ sustituido con uno o más átomos de flúor; Rᵃ es H, alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros, un heterociclilo de 3 a 12 miembros, -OR¹¹, -SR¹⁴, -N(R¹²)₂, -NR¹³OR¹³, -NR¹³S(O)₂R¹³, -NR¹³C(O)R¹³, -N(R¹³)N(R¹³)₂, -N(R¹³)C(O)OR¹³ o -N(R¹³)C(O)N(R¹³)₂, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, el carbociclilo de 3 a 12 miembros y el heterociclilo de 3 a 12 miembros se sustituye opcionalmente con uno o más de R²¹; R² es H, halo, -NO₂, -CN, -N₃, alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros, un heterociclilo de 3 a 12 miembros, -C(O)R¹³, -C(S)R¹³, -C(O)OR¹³, -C(S)SR¹³, -C(O)SR¹³, -C(S)OR¹³, -SC(O)R¹³, -OC(S)R¹³, -SC(S)R¹³, -C(O)N(R¹³)₂, -OR¹¹, -SR¹⁴, -N(R¹²)₂, -N(R¹³)OR¹³, -N(R¹³)S(O)₂R¹³, -N(R¹³)C(O)R¹³, -N(R¹³)N(R¹³)₂, -N(R¹³)C(O)OR¹³, -N(R¹³)C(O)N(R¹³)₂, -S(O)₂R¹³, -S(O)R¹³, -S(O)N(R¹³)₂, -S(O)₂N(R¹³)₂, N⁺(R¹³)₃, -S⁺(R¹³)₂ o -Si(R¹³)₃, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, carbociclilo de 3 a 12 miembros y heterociclilo de 3 a 12 miembros se sustituye opcionalmente con uno o más R²¹; R³ᵃ es H, alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros, un heterociclilo de 3 a 12 miembros, -C(O)R¹³, -C(O)OR¹³, -C(O)N(R¹³)₂, -OR¹¹, -N(R¹²)₂, -N(R¹³)OR¹³, -N(R¹³)S(O)₂R¹³, -N(R¹³)C(O)R¹³, -N(R¹³)N(R¹³)₂, -N(R¹³)C(O)OR¹³, -N(R¹³)C(O)N(R¹³)₂, -S(O)R¹³, -S(O)N(R¹³)₂ o -S(O)₂N(R¹³)₂, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, carbociclilo de 3 a 12 miembros y heterociclilo de 3 a 12 miembros se sustituye opcionalmente con uno o más R²¹; y R³ᵇ es alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros, un heterociclilo de 3 a 12 miembros, -C(O)R¹³, -C(O)OR¹³, -C(O)N(R¹³)₂, -OR¹¹, -N(R¹²)₂, -N(R¹³)OR¹³, -N(R¹³)S(O)₂R¹³, -N(R¹³)C(O)R¹³, -N(R¹³)N(R¹³)₂, -N(R¹³)C(O)OR¹³, -N(R¹³)C(O)N(R¹³)₂, -S(O)R¹³, -S(O)N(R¹³)₂ o -S(O)₂N(R¹³)₂, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, carbociclilo de 3 a 12 miembros y heterociclilo de 3 a 12 miembros se sustituye opcionalmente con uno o más R²¹; o R³ᵃ y R³ᵇ se toman juntos y son alquileno C₂₋₁₂, alquenileno C₂₋₁₂ o alquinileno C₂₋₁₂; donde cada uno del alquileno C₂₋₁₂, alquenileno C₂₋₁₂, alquinileno C₂₋₁₂ y carbociclilo de 3 - 6 miembros se sustituyen opcionalmente con uno o más R²¹; R⁴ es H, halo, -NO₂, -CN, -N₃, alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros, un heterociclilo de 3 a 12 miembros, -C(O)R¹³, -C(S)R¹³, -C(O)OR¹³, -C(S)SR¹³, -C(O)SR¹³, -C(S)OR¹³, -SC(O)R¹³, -OC(S)R¹³, -SC(S)R¹³, -C(O)N(R¹³)₂, -OR¹¹, -SR¹⁴, -N(R¹²)₂, -N(R¹³)OR¹³, -N(R¹³)S(O)₂R¹³, -N(R¹³)C(O)R¹³, -N(R¹³)N(R¹³)₂, -N(R¹³)C(O)OR¹³, -N(R¹³)C(O)N(R¹³)₂, -S(O)₂R¹³, -S(O)R¹³, -S(O)N(R¹³)₂, -S(O)₂N(R¹³)₂, -N⁺(R¹³)₃, -S⁺(R¹³)₂ o -Si(R¹³)₃, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, carbociclilo de 3 a 12 miembros y heterociclilo de 3 a 12 miembros se sustituye opcionalmente con uno o más R²¹; «⁻ ⁻ ⁻ ⁻ ⁻ ⁻» es un enlace simple o un enlace doble, donde cuando «⁻ ⁻ ⁻ ⁻ ⁻ ⁻» es un enlace doble, entonces R⁵ se encuentra ausente; y cuando «⁻ ⁻ ⁻ ⁻ ⁻ ⁻» es un enlace simple, entonces R⁵ es H, halo, -NO₂, -CN, -N₃, alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros, un heterociclilo de 3 a 12 miembros, -C(O)R¹³, -C(S)R¹³, -C(O)OR¹³, -C(S)SR¹³, -C(O)SR¹³, -C(S)OR¹³, -SC(O)R¹³, -OC(S)R¹³, -SC(S)R¹³, -C(O)N(R¹³)₂, -OR¹¹, -SR¹⁴, -N(R¹²)₂, -N(R¹³)OR¹³, -N(R¹³)S(O)₂R¹³, -N(R¹³)C(O)R¹³, -N(R¹³)N(R¹³)₂, -N(R¹³)C(O)OR¹³, -N(R¹³)C(O)N(R¹³)₂, -S(O)₂R¹³, -S(O)R¹³, -S(O)N(R¹³)₂, -S(O)₂N(R¹³)₂, -N⁺(R¹³)₃, -S⁺(R¹³)₂ o -Si(R¹³)₃, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, carbociclilo de 3 a 12 miembros y heterociclilo de 3 a 12 miembros se sustituye opcionalmente con uno o más R²¹; o R⁵ y R³ᵇ se toman junto con los carbonos con los que se acopla cada uno para formar un carbociclilo de 3 - 6 miembros, donde el carbociclilo de 3 - 6 miembros se sustituye opcionalmente con uno o más R²¹; R⁶, en cada aparición, es independientemente halo, -NO₂, -CN, -N₃, alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros, un heterociclilo de 3 a 12 miembros, -C(O)R¹³, -C(S)R¹³, -C(O)OR¹¹, -C(S)SR¹³, -C(O)SR¹³, -C(S)OR¹³, -SC(O)R¹³, -OC(S)R¹³, -SC(S)R¹³, -C(O)N(R¹¹)₂, -OR¹¹, -SR¹⁴, -N(R¹²)₂, -N(R¹³)OR¹³, -N(R¹³)S(O)₂R¹³, -N(R¹³)C(O)R¹³, -N(R¹³)N(R¹³)₂, -N(R¹³)C(O)OR¹³, -N(R¹³)C(O)N(R¹³)₂, -S(O)₂R¹³, -S(O)R¹³, -S(O)N(R¹³)₂, -S(O)₂N(R¹³)₂, -N⁺(R¹³)₃, -S⁺(R¹³)₂ o -Si(R¹³)₃; o dos R⁶ unidos al mismo carbono del anillo para formar un oxo, =NR¹⁴ o alquilideno C₁₋₁₂, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, carbociclilo de 3 a 12 miembros, heterociclilo de 3 a 12 miembros y alquilideno C₁₋₁₂ se sustituye opcionalmente con uno o más R²¹; X es NRᵇ u O; Rᵇ es H, alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros, un heterociclilo de 3 a 12 miembros, -C(O)Rᶜ, -C(O)ORᶜ, -C(O)NRᶜRᶜ, -S(O)₂Rᶜ, -S(O)₂ORᶜ o -S(O)₂NRᶜRᶜ, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, carbociclilo de 3 a 12 miembros y heterociclilo de 3 a 12 miembros se sustituye opcionalmente con uno o más R²¹; Rᶜ, en cada aparición, se selecciona independientemente de H, alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros y un heterociclilo de 3 a 12 miembros, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, carbociclilo de 3 a 12 miembros y heterociclilo de 3 a 12 miembros se sustituye opcionalmente con uno o más R²¹; R¹¹, en cada aparición, se selecciona independientemente de H, alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros, un heterociclilo de 3 a 12 miembros, acilo C₁₋₁₂ y -Si(R¹³)₃, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, carbociclilo de 3 a 12 miembros, heterociclilo de 3 a 12 miembros y acilo C₁₋₁₂ se sustituye opcionalmente con uno o más R²¹; R¹², en cada aparición, se selecciona independientemente de H, alquilo C₁₋₁₂, alcoxi C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros, un heterociclilo de 3 a 12 miembros y -Si(R¹³)₃, donde cada uno del alquilo C₁₋₁₂, alcoxi C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, carbociclilo de 3 a 12 miembros y heterociclilo de 3 a 12 miembros se sustituye opcionalmente con uno o más R²¹; R¹³, en cada aparición, se selecciona independientemente de H, alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros y un heterociclilo de 3 a 12 miembros, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, carbociclilo de 3 a 12 miembros y heterociclilo de 3 a 12 miembros se sustituye opcionalmente con uno o más R²¹; R¹⁴, en cada aparición, se selecciona independientemente de H, alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros, un heterociclilo de 3 a 12 miembros y acilo C₁₋₁₂, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, carbociclilo de 3 a 12 miembros, heterociclilo de 3 a 12 miembros y acilo C₁₋₁₂ se sustituye opcionalmente con uno o más R²¹; R²¹, en cada aparición, se selecciona independientemente de halo, -OH, -S(O)₂R¹⁶, alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, alcoxi C₁₋₁₂, un carbociclilo de 3 a 12 miembros y un heterociclilo de 3 a 12 miembros, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, alcoxi C₁₋₁₂, carbociclilo de 3 a 12 miembros y heterociclilo de 3 a 12 miembros se sustituye opcionalmente con 1 a 3 grupos que se seleccionan de halo, -OH, alquilo C₁₋₄ y alcoxi C₁₋₄; R¹⁶, en cada aparición, se selecciona independientemente de H o alquilo C₁₋₁₂; n es 0 o un entero de 1 a 8; p es 0, 1 ó 2; y q es 1, 2 ó 3, siempre que la suma de p y q no sea 4 ni 5.
ARP170103684A 2016-12-27 2017-12-26 Activador de nrf2 AR110590A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662439289P 2016-12-27 2016-12-27

Publications (1)

Publication Number Publication Date
AR110590A1 true AR110590A1 (es) 2019-04-10

Family

ID=61007836

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103684A AR110590A1 (es) 2016-12-27 2017-12-26 Activador de nrf2

Country Status (21)

Country Link
US (2) US10968181B2 (es)
EP (2) EP3875450A1 (es)
JP (1) JP7088933B2 (es)
KR (1) KR20190111949A (es)
CN (1) CN110382475A (es)
AR (1) AR110590A1 (es)
AU (1) AU2017387070B2 (es)
BR (1) BR112019013341A2 (es)
CA (1) CA3048849A1 (es)
CL (1) CL2019001804A1 (es)
CO (1) CO2019008110A2 (es)
CR (1) CR20190344A (es)
EA (1) EA201991595A1 (es)
ES (1) ES2878102T3 (es)
IL (1) IL267692B (es)
JO (1) JOP20190163B1 (es)
MX (1) MX2019007826A (es)
PE (1) PE20191488A1 (es)
TW (1) TW201827406A (es)
UY (1) UY37551A (es)
WO (1) WO2018125880A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210099622A (ko) 2018-12-05 2021-08-12 가부시키가이샤 스코히아 파마 거대고리 화합물 및 그의 용도
CN112679328B (zh) * 2019-10-17 2023-09-15 南京药石科技股份有限公司 一种3-三氟甲基-2-环己烯-1-酮的工业化生产方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JP2008110962A (ja) * 2006-08-02 2008-05-15 Santen Pharmaceut Co Ltd Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤
CN102066397B (zh) 2008-04-18 2013-09-11 里亚塔医药公司 包含抗炎症药效团的化合物以及使用方法
US9139592B2 (en) 2010-06-14 2015-09-22 Trt Pharma Inc. Modulators of Nrf2 and uses thereof
AU2012222074A1 (en) * 2011-02-25 2013-09-12 National Institutes Of Health Chalcone derivatives as Nrf2 activators
US20170354639A1 (en) * 2014-10-24 2017-12-14 Biogen Ma Inc. Diterpenoid derivatives and methods of use thereof
RU2018101077A (ru) * 2015-06-15 2019-07-15 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Регуляторы nrf2

Also Published As

Publication number Publication date
KR20190111949A (ko) 2019-10-02
CN110382475A (zh) 2019-10-25
US20190345112A1 (en) 2019-11-14
US10968181B2 (en) 2021-04-06
MX2019007826A (es) 2019-10-24
EP3562816A1 (en) 2019-11-06
JP7088933B2 (ja) 2022-06-21
BR112019013341A2 (pt) 2019-12-24
AU2017387070B2 (en) 2022-03-24
CR20190344A (es) 2019-11-19
CA3048849A1 (en) 2018-07-05
CL2019001804A1 (es) 2019-11-15
EP3562816B1 (en) 2021-01-20
IL267692B (en) 2021-09-30
JOP20190163B1 (ar) 2023-09-17
EP3875450A1 (en) 2021-09-08
TW201827406A (zh) 2018-08-01
WO2018125880A8 (en) 2019-06-06
UY37551A (es) 2018-07-31
EA201991595A1 (ru) 2020-01-27
IL267692A (en) 2019-08-29
US20210340107A1 (en) 2021-11-04
JP2020503332A (ja) 2020-01-30
PE20191488A1 (es) 2019-10-21
ES2878102T3 (es) 2021-11-18
CO2019008110A2 (es) 2019-08-20
AU2017387070A1 (en) 2019-08-15
JOP20190163A1 (ar) 2019-06-27
WO2018125880A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
AR111407A1 (es) Compuestos inhibidores de ask1 y usos de los mismos
AR105836A1 (es) Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk
AR100233A1 (es) Composición de limpieza
AR107694A1 (es) Heteroarilos inhibidores de pad4
AR107488A1 (es) Compuestos de benzopirazol y análogos de éstos
AR116694A1 (es) COMPUESTOS AGONISTAS b DEL RECEPTOR DE LA HORMONA TIROIDEA
AR115697A1 (es) Tiofenocarboxamidas sustituidas y análogos de las mismas
AR092347A1 (es) Derivados de azaindol
AR111689A1 (es) Tienopiridinas y benzotiofenos útiles como inhibidores de irak4
AR109709A1 (es) Inhibidores de la fosfatidilinositol 3-quinasa
AR099994A1 (es) Compuesto de ciclopropanamina y sus usos
AR106293A1 (es) Moduladores del receptor x farnesoide
AR110590A1 (es) Activador de nrf2
AR090862A1 (es) Compuestos de tetrazolinona y su uso para combatir plagas
CL2017000103A1 (es) Derivados de bis(aril)catecol como herbicidas
BR112016024443A2 (pt) composto, composição e mistura herbicida e método para o controle do crescimento da vegetação indesejada
AR106652A1 (es) Compuestos para tratar la esclerosis lateral amiotrófica
MD4626C1 (ro) Derivaţi de tamoxifen pentru tratamentul afecţiunilor neoplazice, în special cu nivel înalt de proteină HER2
CO2022008968A2 (es) Nuevos derivados de metilquinazolinona
CL2019001041A1 (es) Compuestos terapéuticos y métodos para utilizarlos.
CR20170134A (es) Método para preparar 2´-o-fucosil-lactosa
AR108876A1 (es) Formulaciones y composiciones de análogos de hidroximetionina y procesos para preparar las formulaciones
CL2020000376A1 (es) Compuesto pentacíclico.
AR102246A1 (es) Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de osteoporosis, usos
AR072119A1 (es) Productos que son compuestos derivados de pirroloindol inhibidores de hsp90, composiciones farmaceuticas que los contienen; utilizacion de los compuestos para la preparacion de medicamentos; dichos medicamentos constituidos por los compuestos activos e intermediarios de sintesis de dichos compuestos

Legal Events

Date Code Title Description
FB Suspension of granting procedure